Black Diamond Therapeutics Inc. (BDTX)
BDTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/0001701541-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BDTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001701541 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $70.0M |
| Net income | $22.4M |
| Operating income | $12.5M |
| Net margin | 32.0% |
| Operating margin | 17.9% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $21.0M |
| Total assets | $143.0M |
| P/E (computed) | 3.9× |
| P/S (computed) | 1.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $15.1M cash; operating cash flow -$8.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 57,468,255 (2026-11-05); 56,974,913 a year earlier; 51,635,184 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$10.0M | -$8.3M | $15.1M | No debt tags | $0 | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $0 | -$9.9M | -$8.0M | $19.2M | No debt tags | $0 | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $0 | -$9.0M | -$10.2M | $30.1M | No debt tags | $0 | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $0 | -$15.1M | -$6.8M | $21.0M | No debt tags | $70.0M | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $0 | -$8.5M | -$7.8M | $30.9M | No debt tags | $70.0M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $0 | -$10.6M | -$9.2M | $30.0M | No debt tags | $70.0M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $70.0M | $56.5M | $53.4M | $98.4M | No debt tags | $70.0M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $0 | -$16.0M | -$15.1M | $36.4M | No debt tags | $0 | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-11-13 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 487 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.3% |
| 1 month | -12.5% |
| 3 months | -27.2% |
| Year to date | -39.5% |
| 1 year | -67.3% |
| From 52-week high | -63.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics Inc. | $0.3960 | -4.12% | $96.4M |
| CHRS | Coherus Oncology Inc. | $0.5059 | -3.73% | $78.2M |
| MOLN | Molecular Partners AG | $2.70 | -8.21% | $101.2M |
| VYGR | Voyager Therapeutics Inc. | $1.63 | -5.78% | $101.4M |
| TNYA | Tenaya Therapeutics Inc. | $0.3336 | -4.47% | $76.0M |
| AVXL | Anavex Life Sciences Corp. | $0.8176 | -12.42% | $75.8M |
| ZURA | Zura Bio Limited | $1.08 | -12.90% | $104.0M |
| ARMP | Armata Pharmaceuticals Inc. | $2.99 | -22.74% | $111.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier